Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine

Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Access to genomic testing, not therapy cost, is the biggest challenge

Africa CDC warns of regional Ebola spread risk as DRC and Uganda confirm outbreaks

Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration

Lupin launches Atharv ability neuro-rehabilitation centre in Delhi

New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches